Publication | Closed Access

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

Family MedicineBone Marrow FailureHematologyClinical TrialsPharmacotherapyRigosertib VersusMedicineOsteoporosisPhase 3Health Sciences